The B-VAX Project: Providing hepatitis B vaccinations through assertive outreach to people who inject drugs.

Not Applicable

Recruiting

• Conditions: The Hepatitis B Virus (HBV).; Public Health - Other public health; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Infection - Other infectious diseases

• Registration Number: ACTRN12612001308886
• Lead Sponsor: The Burnet Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-12-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Current Burnet Institute cohort study participants who are serologically confirmed as being susceptible to contracting HBV.

Exclusion Criteria

Serological evidence of successful immunity to HBV through either previous exposure or vaccination.
Not being currently enrolled in a Burnet Institute cohort study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Increase HBV vaccination coverage among participants of current Burnet Institute cohort studies of people who inject drugs (PWID) by delivering the HBV vaccine to HBV susceptible participants. This outcome will be assessed upon completion of the B-VAX project by reviewing the proportion of participants successfully vaccinated within the cohort. [Baseline- 15 months]

Secondary Outcome Measures

Name	Time	Method
Investigate the feasibility and acceptability of providing HBV vaccination to PWID using an outreach model through analysis of the qualitative data. [Baseline- 15 months];Evaluate the effectiveness of the outreach model for HBV vaccination delivery, completion and HBV Surface antibody seroconversion through analysis of the qualitative data, vaccine course completion rates and seroconversion amongst fully vaccinated study participants. This data will be compared to the outcomes of similar studies. [15 months];Measure the efficacy of the standard vs. opportunistic accelerated schedule in terms of serological immune response and vaccination completion rates.[15 months]